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Abstract
Background:  Adenine nucleotide translocase (ANT) is located in the inner mitochondrial
membrane and catalyzes the exchange of mitochondrial ATP for cytosolic ADP. ANT has been
known to be a major component of the permeability transition pore complex of mitochondria and
contributes to mitochondria-mediated apoptosis. Human ANT has four isoforms (ANT1, ANT2,
ANT3, and ANT4), and the expression of the ANT isoforms is variable depending on the tissue
and cell type, developmental stage, and proliferation status. Among the isoforms, ANT1 is highly
expressed in terminally-differentiated tissues, but expressed in low levels in proliferating cells, such
as cancer cells. In particular, over-expression of ANT1 induces apoptosis in cultured tumor cells.
Methods: We applied an ANT1 gene transfer approach to induce apoptosis and to evaluate the
anti-tumor effect of ANT1 in a nude mouse model.
Results: We demonstrated that ANT1 transfection induced apoptosis of MDA-MB-231 cells,
inactivated NF-κB activity, and increased Bax expression. ANT1-inducing apoptosis was
accompanied by the disruption of mitochondrial membrane potential, cytochrome c release and
the activation of caspases-9 and -3. Moreover, ANT1 transfection significantly suppressed tumor
growth in vivo.
Conclusion: Our results suggest that ANT1 transfection may be a useful therapeutic modality for
the treatment of cancer.
Background
Apoptosis is a programmed form of cell death, and as
such, differs fundamentally from cellular necrosis. Apop-
tosis is characterized by genetically-controlled cellular
auto-digestion via the activation of endogenous proteases
[1]. Apoptosis results in cytoskeletal disruption, cell
shrinkage, membrane blebbing, nuclear condensation,
and inter-nucleosomal DNA fragmentation [1,2]. Moreo-
ver, apoptosis is essentially required for the homeostasis
of normal tissues and to manage cellular disruption
caused by mutations. Hence, the disruption of the apop-
totic process is involved in the pathogenesis of many
human diseases, including viral infections, autoimmune
diseases, and cancers. In particular, progressive perturba-
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tions of the normal apoptotic pathway occur during neo-
plastic transformation, progression, and metastasis [3],
and thus apoptosis-related genes are attractive cancer
treatment developmental targets [4].
Adenine nucleotide translocase (ANT) participates in
ATP-for-ADP exchange through the inner mitochondrial
membrane, which supplies the cytoplasm with newly syn-
thesized ATP for oxidative phosphorylation [5]. Recently,
it has been reported that death receptor-initiated pathway,
mediated by RIP, disrupts the interaction between cyclo-
philin D and ANT and permits the binding of zVAD.fmk
(zVAD) to ANT, which prevents ANT from adopting the
conformational c-state and subsequently results in inhibi-
tion of ADP/ATP exchange, the reduction of cellular ATP,
and necrotic cell death [6].
Four closely related isoforms of ANT (ANT1, 2, 3, and 4)
exist in humans, and these are expressed in a tissue-spe-
cific manner [7]. ANT1 is predominantly expressed in the
heart, skeletal muscle, and brain; ANT2 is predominantly
expressed in the liver and in cells with increased prolifer-
ative activity; and ANT3 is ubiquitously detected [8].
ANT1 was first identified as an apoptosis-inducing pro-
tein. ANT1 over-expression induces rapid cell death with
a concomitant decrease in Δψm and an increase in nucle-
osomal DNA degradation [9,10]. However, in the major-
ity of cancer cell lines, ANT1 expression is minimal,
whereas the expression of ANT2, an alleged anti-apoptotic
molecule, is high [11]. In cancer cell lines, up-regulation
of ANT1 expression resulted in the recruitment of an I-
κBα-NF-κB-complex into mitochondria and a concomi-
tant decrease in nuclear factor kappa B (NF-κB) binding
activity [12]. Increasing evidences suggest that NF-κB
plays an important role in tumor development and pro-
gression [13]. Moreover, constitutive NF-κB activation
due to signaling defects, mutations, or chromosomal rear-
rangements has been identified in a wide variety of can-
cers [13,14], and thus the constitutive activation of NF-κB
is viewed as an obstacle to effective cancer therapy [15].
We hypothesized that ANT1 gene transfer into cancer cells
would inhibit cell growth and induce apoptosis through
NF-κB inactivation, and investigated the anti-cancer effect
of ANT1 over-expression in vitro and in vivo using a nude
mouse model.
Methods
Cell line and culture
MDA-MB-231 cells were used throughout this study and
were purchased from the Korean Cell Line Bank (Seoul,
Korea). MDA-MB-231 cells were cultured in DMEM
medium supplemented with 10% fetal bovine serum
(FBS), 100 units/ml penicillin, and 100 μg/ml streptomy-
cin in a humidified 5% CO2/95% air atmosphere at 37°C.
Reverse transcription-PCR (RT-PCR)
Cancer cell lines were collected and total RNA was
extracted using Trizol (Invitrogen, Carlsbad, CA, USA),
according to the manufacturer's instructions. For reverse
transcription-polymerase chain reaction (RT-PCR) analy-
sis, 5 μg of total RNA was reverse-transcribed using RT-
PCR kits (Promega, Madison, WI, USA). PCR was used to
amplify target cDNA under the following conditions: 35
cycles at 94°C for 1 minute, 55°C for 1 minute, and 72°C
for 2 minutes. PCR products were analyzed using standard
agarose gel electrophoresis. The primers used for RT-PCR
were as follows; ANT1 forward 5'-ACAGATTGTGTGGTTT-
3' and reverse 5'-TTTTGTGCATTAAGTGGTCTTT-3, and β-
actin forward 5'-GGAAATCGTGCGTGACA TTAAGG-3'
and reverse 5'-GGCTTTTAGGATGGCAAGGGAC-3'.
Transfection
ANT1 expression vector (pcDNA 3.1-ANT1) was kindly
provided by Dr. S. Grim (Max-Planck Institute, Berlin,
Germany). To transfect MDA-MB-231 cells with plasmid
vector, cells were plated into either 6-well plates (2 × 105
cells per well) or a 100 mm dish (2 × 106 cells) and
allowed to adhere for 24 hours. Lipofectamine 2000 (Inv-
itrogen) was used for the transfection, and after
pcDNA3.1 or pcDNA3.1-ANT1 transfection, cells were
cultured for 4 hours and then the medium was replaced
with fresh medium supplemented with 10% fetal bovine
serum. Cells were harvested 24–48 hours after transfec-
tion.
FACS cytometric analysis of apoptotic cells
Approximately 2 × 105/ml MDA-MB-231 cells were trans-
fected with ANT1 and cultured for the indicated length of
time. Cells were then harvested, washed twice with PBS,
and incubated with reagent containing Annexin V conju-
gated with fluorescence isothiocyanate (FITC; 2.5 μg/ml)
and propidium iodide (PI, 5 μg/ml; BD Pharmingen, San
Diego, CA, USA) for 15 min at room temperature. Cells
were analyzed using a flow cytometer (Epics XL; Coulter,
Marseille, France).
Measurement of mitochondrial membrane potentials 
(Δψm)
To measure levels of Δψm disruption, cells were harvested,
washed twice with PBS, and then incubated with 20 nM
3,3'-diethyloxacarbocyanine (DiOC6; Molecular Probes,
Eugene, OR, USA) for 15 min at 37°C. Δψm values were
determined by a flow cytometer (Epix XL).
DNA fragmentation assays
Cells were subjected to DNA fragmentation analysis on
2% agarose gels. Where indicated, cells were transfected
with ANT1.BMC Cancer 2008, 8:160 http://www.biomedcentral.com/1471-2407/8/160
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Western blotting
Prepared cytosolic, nuclear, or mitochondrial lysates were
analyzed for protein content using Bradford reagent (Bio-
Rad, Hercules, CA, USA). Briefly, 50 μg of total protein
was electrophoresed in 10% SDS-PAGE gel, transferred to
a polyvinylidene difluoride membrane (Millipore, Bed-
ford, MA, USA), and incubated with monoclonal anti-NF-
κB, anti-Bcl-xL, anti-Bax, anti-cyt c, anti α-tubulin (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), anti-caspase-
9 (BD Pharmingen), anti-caspase-3 (Stressgen, Victoria,
Canada), anti-phospho-Akt, or anti-Akt antibodies (Cell
Signaling Technology, Berverly, MA, USA). Immunoblots
were visualized by enhanced chemiluminescence (Amer-
sham Pharmacia Biotech, Uppsala, Sweden).
Confocal microscopy
Cells were grown in Lab-tek chamber slides (177429;
NUNC, Naperville, IL, USA). After fixing cells for 10 min-
utes at room temperature, cells were washed four times
with filtered PBS and blocked with 3% fetal bovine serum
in 1% BSA/PBS for 30 minutes at room temperature. Cells
were then washed three times with filtered PBS and incu-
bated overnight at 4°C with monoclonal anti-NF-κB pri-
mary antibodies (Santa Cruz Biotechnology). After three
washes, cells were incubated with FITC-conjugated sec-
ondary antibodies or DAPI for 30 minutes at room tem-
perature. Images were obtained using a LSM510 unit (Carl
Zeiss, Jena, Germany).
NF-κB reporter gene assay
The NF-κB-luciferase-reporter construct containing four
tandem NF-κB signal binding motifs (Clontech, Palo Alto,
CA, USA) was co-transfected with pcDNA3.1 or
pcDNA3.1-ANT1 into MDA-MB-231 cells using Lipo-
fectamine 2000 (Invitrogen), and cultured for the indi-
cated times. Culture media were then removed, cells were
rinsed gently with PBS, and 200 μl of 1 × lysis buffer was
added per well. Cells were then incubated with 1 × lysis
buffer at 4°C for 15–20 minutes and one freeze-thaw
cycle was also performed to achieve complete lysis. Cell
lysates were then transferred to pre-labeled microcentri-
fuge tubes and centrifuged at 12,000 g for 4 minutes at
4°C. Supernatant fractions (cell extracts) were recovered
and luciferase activities were determined using a single-
sample luminometer (FB12 luminometer; Berthold
Detection Systems, Pforzheim, Germany).
In vivo study
A tumor model was established in 6- to 8-week-old Balb/
c nude mice by subcutaneous injection of 5 × 106 MDA-
MB-231 cells. Therapy was started 2 weeks after tumor
inoculation, when the tumor volume reached approxi-
mately 100 mm3. pcDNA3.1 (as a vector controls) or
pcDNA3.1-ANT1 (100 μg) with Lipofectamine 2000 (100
μl) were administrated by intratumoral injection twice per
day on post-challenge day 15 and 16. Tumor size was
measured with a caliper every 3 or 7 days for 40 days, and
tumor volumes were calculated using m1
2 × m2 × 0.5236
(where m1 represents tumor short axis and m2 long axis)
[16].
Statistical analysis
Data were analyzed using Student's t test, and a p value of
< 0.05 was considered to be statistically significant in the
experiments.
Results
1. ANT1 expression was low in various human cancer cell 
linesand the over-expression of ANT1 by transfection of 
pcDNA 3.1-ANT1 induced apoptotic cell death in vitro
We first determined the expression levels of ANT1 in vari-
able human cancer cell lines to investigate the availability
of ANT1 as a target for cancer gene therapy. ANT1 expres-
sion measured by RT-PCR was very low in many human
cancer cells examined (Fig. 1A). Especially, ANT1 was
scarcely detected in human breast cancer cell lines, includ-
ing MCF7, MDA-MB-231, and SK-BR-3. Based on these
results, human breast cancer cell lines were used through-
out further study. Over-expression of ANT1 in MDA-MB-
231 cells through transfection of pcDNA3.1-ANT1 vector
induced cell death by 30–40% after 24 hours as deter-
mined by Annexin V-PI staining and FACS analysis (Fig.
1B). DNA laddering was also observed in MDA-MB-231
cells transfected with pcDNA3.1-ANT1 (Fig. 1C). These
results demonstrated that over-expression of ANT1 by
pcDNA3.1-ANT1 induced apoptotic cell death.
2. Over-expression of ANT1 significantly decreased NF-κB 
activity
To evaluate the effect of ANT1 over-expression on the NF-
κB activity, MDA-MB-231 cells were transfected with
pcDNA3.1-ANT1 for 12 hours and subjected to confocal
microscopy, Western blotting, and Luciferase assay. These
analyses were performed before apoptotic cell death was
induced. The results obtained showed that ANT1 transfec-
tion significantly decreased NF-κB translocation to the
nucleus in MDA-MB-231 cells (Fig. 2A and 2B). Luciferase
assays also showed that transcriptional activity of NF-κB
was inhibited in ANT1-transfected cells (Fig. 2C). These
results suggested that ANT1 transfection induced inactiva-
tion of NF-κB in MDA-MB-231 cells, and thereby, subse-
quently caused apoptotic cell death.
3. Apoptotic signaling pathway was regulated byover-
expression of ANT1
Next, we investigated the apoptotic-signaling pathways
involving in the ANT1 transfection-induced apoptosis of
MDA-MB-231 cells. ANT1 transfection down-regulated
Akt activation (Akt phosphorylation) and Bcl-xL protein
levels, but, significantly increased Bax-α (a pro-apoptoticBMC Cancer 2008, 8:160 http://www.biomedcentral.com/1471-2407/8/160
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Expression of ANT1 in various human cancer cells and the effect of ANT1 expression vector in human breast cancer cells Figure 1
Expression of ANT1 in various human cancer cells and the effect of ANT1 expression vector in human breast 
cancer cells. A. To evaluate the levels of ANT1 expression levels in human cancer cell lines from various origins (SNU668, 
SNU719, SNU638, NCI-H358, A549, NCI-H889, SK-HEP-1, SNU449, SNU423, SK-OV-3, SNU8, SNU840, MCF7, MDA-MB-
231, and SK-BR-3), total RNA was extracted and subjected to RT-PCR using specific primers for human ANT1 or β-actin as an 
internal control. B. Cells were transfected with pcDNA-ANT1; 24 hours later, the cells were stained with Annexin V-FITC and 
PI, and cell death was analyzed by flow cytometry. C. DNA fragmentation was nduceded by ANT1 over-expression Cells were 
transfected with pcDNA-ANT1 and 24 hours later, the total genomic DNA was extracted and DNA fragmentation was ana-
lyzed by 2% agarose gel electrophoresis.BMC Cancer 2008, 8:160 http://www.biomedcentral.com/1471-2407/8/160
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Over-expression of ANT1 decreased the activity of NF-κB Figure 2
Over-expression of ANT1 decreased the activity of NF-κB. A. ANT1 transfection reduced nuclear translocation of NF-
κB by ANT1 over-expression. MDA-MB-231 cells were transfected with pcDNA-ANT1 and 12 hours later cells were blocked 
with 3% fetal bovine serum in 1% BSA/PBS for 30 min, washed with PBS three times, and incubated overnight with anti-NF-κB 
antibody. After washing three times, cells were incubated with anti-IgG-FITC or DAPI for 30 min. Images were obtained using 
a LSM510. B. ANT1 transfection reduced the nuclear translocation of NF-κB by ANT1 over-expression. Cells were trans-
fected with pcDNA-ANT1; 12 hours later, total or nuclear extracts were prepared and Western blotted using anti-NF-κB or 
anti-α-tubulin antibodies. Immunoblots were visualized using an enhanced chemiluminescence detection system. C. ANT1 
transfection reduced the transcriptional activity of NF-κB induced by ANT1 over-expression. Cells were co-transfected with 
pcDNA-ANT1 and NF-κB-luciferase reporter construct for 12 hours and then lysed. Lysate luciferase activities were deter-
mined using a luminometer.BMC Cancer 2008, 8:160 http://www.biomedcentral.com/1471-2407/8/160
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Bcl-2 family member) levels (Fig. 3A). Mitochondrial
membrane potential (MMP) was also destroyed by ANT1
transfection, as determined by DiOC6 staining (Fig. 3B).
Furthermore, apoptosis induced by ANT1 over-expression
was accompanied by enhanced cytochrome c release, and
caspases-9 and -3 activation (Fig. 3C.). All the data indi-
cated that ANT1 transfection induced mitochondria-
mediated apoptosis in MDA-MB-231 cells.
4. ANT1 transfection significantly inhibited tumor growth 
in vivo
Finally, in order to evaluate the therapeutic effect of
pcDNA3.1-ANT1  in vivo, we established in vivo tumor
model by subcutaneous injection of MDA-MB-231 cells
into female Balb/c nude mice. Two weeks after tumor cell
challenge, when the tumor volume reached approxi-
mately 100 mm3, mice were allocated into two groups for
therapy. On day 15 and 16 after tumor cell challenge,
mice were twice treated with 100 ug/100 ul pcDNA 3.1
complex with Lipofectamine 2000 in group 1 (control
group, n = 5), or with 100 ug/100 ul pcDNA 3.1-ANT1
complex with Lipofectamine 2000 in group2 (therapy
group, n = 5) via intratumoral injection. On day 23 (one
week after treatment), tumor cells were isolated from
tumor tissue of mice, and total RNA was extracted and
subjected to RT-PCR to assess the ANT1 expression. We
also performed PCR using the total RNAs as template as a
negative control of PCR to exclude the plasmid contami-
nation during the RNA extraction from tumor tissues.
ANT1 was over-expressed in tumor of mice treated with
pcDNA 3.1-ANT1 but not in control mice treated with
pcDNA 3.1 (Fig. 4B). Tumor volumes were measured
weekly throughout the experiment for 40 days (Fig. 4A).
The tumor volumes of pcDNA 3.1-ANT1-treated mice
were significantly smaller than those of control mice (p <
0.05). At the end of observation (day 40), tumor growth
was inhibited up to 50% in pcDNA 3.1-ANT1-treated
mice, compared with control mice (Fig. 4C). On day 40,
total DNA was extracted for DNA fragmentation assay.
DNA laddering was observed in tumor cells of mice
treated with pcDNA 3.1-ANT1 (Fig 4B), which means that
apoptotic cell death rather than cell cycle arrest might be
involved in the suppression of tumor growth by pcDNA
3.1-ANT1 treatment. All of these in vivo results suggest that
transfection of ANT1 expression vector into tumor cells
could exert an anti-tumor effect in vivo partly by inducing
apoptotic cell death.
Discussion
Mitochondria are required for cellular bioenergetics and
play a central role in determining the 'point of no return'
in the apoptotic process [17]. The most commonly used
cancer therapeutics eliminate tumors by inducing apopto-
sis [18,19]. Moreover, apoptotic signaling pathways
involve mitochondrial membrane permeabilization, an
event referred to as the 'central executioner' of apoptosis
[20]. During this process, the mitochondrial outer and
inner membranes are both permeabilized, which results
in the release of soluble proteins from mitochondria, and
results in activated proteases and nucleases beginning to
break down the cell [21].
ANT1 is a component of the mitochondrial permeability
transition pore (MPTP) and the most abundant protein in
the mitochondrial inner membrane (IM; 22). MPTP is a
protein complex found in mitochondrial contact sites and
when it is opened acts as a non-specific channel that
allows free passage of molecules < 1500 Da in size
through the IM [23]. As a consequence, the MMP is
reduced and the mitochondria become swollen. MPTP
opening is regulated by Bcl-2 family members, such as Bax
and Bcl-2, and whereas Bax activates this opening, Bcl-2
inhibits it. Moreover, during this process of MPTP open-
ing, ANT1 interacts with Bax or Bcl-2 [24,25]. In terms of
the role of NF-κB in cancer, NF-κB inhibition by ANT1
over-expression may be an effective way of suppressing
tumor cell proliferation. ANT1 over-expression resulted in
the recruitment of the I-κBα-NF-κB-complex into the
mitochondria and a concurrent decrease in nuclear NF-κB
binding activity [12]. ANT1 overexpression could be
broadly applied for therapy to decrease Bcl-2 levels or
inhibit NF-κB activity in various human cancers. Addi-
tionally, Bcl-2 or NF-κB over-expression occurs in many
cancer types and is associated with chemoresistance.
Recently, ANT1 over-expression was shown to increase the
chemotherapeutic effect using all-trans retinoic acid [26].
Although ANT isoforms are of central importance with
respect to MTMP, and play a major role in apoptosis, only
one study has described the potential therapeutic use of
ANT2 as an anti-cancer agent based on the results of
siRNA knock-down studies [27]. In the present study, we
adopted a gene therapy approach using ANT1 to trigger
cancer cell apoptosis. ANT1 over-expression resulted in
cancer cell apoptosis in vitro and in vivo through inactiva-
tion of Akt and NF-κB, and mitochondria-mediated apop-
totic pathway, and effectively suppressed tumor growth in
vivo. Moreover, we achieved a synergistic effect by combi-
nation of ANT1 over-expression with cytotoxic drugs,
such as a genistain or gemcitabine, for cancer therapy
(data not shown).
Based on the preceding results of the present study, we
suggest that ANT1 gene transfer might be an efficient strat-
egy to suppress tumor growth and to sensitize cancer cells
to chemotherapeutic agents. However, according to the
reference [28], efficiency of in vivo gene transfer into
tumors by Lipofectamine2000 is only about 2%. In our
experiments, single intratumoral administration of
pcDNA-ANT1 complex with Lipofectamine2000 in vivoBMC Cancer 2008, 8:160 http://www.biomedcentral.com/1471-2407/8/160
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Apoptotic signaling was regulated by ANT1 transfection Figure 3
Apoptotic signaling was regulated by ANT1 transfection. A. ANT1 transfection induced Akt inactivation, reduced Bcl-
xL expression, and Bax induction. Cells were transfected with pcDNA-ANT1 for 12 hours, and then total or nuclear extracts 
were prepared and Western-blotted using anti-phospho-Akt, anti-Akt, anti-Bcl-xL, anti-Bax, or anti-α-tubulin antibodies. 
Immunoblots were visualized by enhanced chemiluminescence. B. Mitochondrial membrane potential disruption induced by 
ANT1 transfection. Cells were transfected with pcDNA-ANT1 for 12 hours and then stained with DiOC6. Mitochondrial 
membrane potentials were quantified by flow cytometry. C. Caspases-9 and -3 activation induced by ANT1 transfection. Cells 
were transfected with pcDNA-ANT1 for 24 hours. Cytoplasmic extracts were then prepared and Western-blotted using anti-
caspase-9, anti-caspase-3, or anti-α tubulin antibodies. Immunoblots were visualized by enhanced chemiluminescence.BMC Cancer 2008, 8:160 http://www.biomedcentral.com/1471-2407/8/160
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Over-expression of ANT1 inhibits tumor growth in vivo Figure 4
Over-expression of ANT1 inhibits tumor growth in vivo. A. Animal experimental schedule is described in detail in 
Materials and Methods. Briefly, mice were challenged with MDA-MA-213 cells via subcutaneous injection. On day 15 and 16 
after tumor cell challenge, mice were treated with pcDNA (group1) or pcDNA-ANT1 (group2) via intratumoral injection. B. 
On day 23, tumor cells were isolated from tumor tissues from sacrificed extra mice, and total RNA was extracted and sub-
jected to RT-PCR to evaluate the expression of ANT1. On day 40, total DNA was also extracted and subjected to DNA frag-
mentation assay. C. Tumor volumes were measured weekly using a caliper for 40 days after tumor cell challenge. Tumor 
volumes were calculated by m1
2 × m2 × 0.5236, (where m1 = short tumor axis and m2 = long tumor axis).BMC Cancer 2008, 8:160 http://www.biomedcentral.com/1471-2407/8/160
Page 9 of 9
(page number not for citation purposes)
could not effectively inhibit tumor growth, which was
probably due to the low efficiency of gene delivery. There-
fore, the development of newer gene delivery system to
enhance transfection efficiency is necessary for more effec-
tive cancer gene therapy targeting ANT'1.
Conclusion
Our results show that ANT1 transfection inactivates NF-
κB, induces apoptosis, and inhibits tumor growth in vitro
and in vivo. These results may not be limited to specific
cancer cell types, and thus ANT1 gene regulation of
tumor-specific promoters might be used in therapy for
various types of cancer. Further studies, including clinical
trials, are needed to overcome low gene delivery efficiency
in vivo.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
J–YJ performed most of the experiments and was respon-
sible for producing the results, data analysis, and prepar-
ing the manuscript; YC and KCYA contributed to the
conduction of additional experiments; Y–KJ was responsi-
ble for analysis of data and writing of the paper; C–WK
contributed to the design of the project, data analysis and
writing of the paper. All authors reviewed and agreed the
final manuscript.
Acknowledgements
This work was supported in part by grants from The Cancer Research 
Center the Korean Science & Engineering Foundation (KOSEF) through the 
Tumor Immunity Medical Research Center at Seoul National University 
College of Medicine, Korea.
References
1. Gorczyca W, Melamed MR, Darzynkiewicz Z: Programmed death
of cells (apoptosis).  Patol Pol 1993, 44:113-119.
2. van Delft MF, Huang DC: How the Bcl-2 family of proteins inter-
act to regulate apoptosis.  Cell Res 2006, 16:203-213.
3. Cotter TG, Lennon SV, Glynn JG, Martin SJ: Cell death via apopto-
sis and its relationship to growth, development and differen-
tiation of both tumor and normal cells.  Anticancer Res 1990,
10:1153-1159.
4. Fulda S, Debatin KM: Modulation of apoptosis signaling for can-
cer therapy.  Arch Immunol Ther Exp (Warsz) 2006, 54:173-175.
5. Klingenberg M: Energetic aspects of transport of ADP and
ATP through the mitochondrial membrane.  Ciba Found Symp
1975, 31:105-124.
6. Flierl A, Chen Y, Coskun PE, Samulski RJ, Wallace DC: Adeno-asso-
ciated virus-mediated gene transfer of the heart/muscle ade-
nine nucleotide translocator (ANT) in mouse.  Gene Ther 2005,
12:570-578.
7. Lunardi J, Attardi G: Differential regulation of expression of the
multiple ADP/ATP translocase genes in human cells.  J Biol
Chem 1991, 266:16534-16540.
8. Doerner A, Pauschinger M, Badorff A, Noutsias M, Giessen S, Schulze
K, Bilger J, Rauch U, Schultheiss HP: Tissue-specific transcription
pattern of the adenine nucleotide translocase isoforms in
humans.  FEBS Lett 1997, 414:258-262.
9. Bauer MK, Schubert A, Rocks O, Grimm S: Adenine nucleotide
translocase-1, a component of the permeability transition
pore, can dominantly induce apoptosis.  J Cell Biol 1999,
147:1493-1502.
10. Halestrap AP: Mitochondrial permeability: dual role for the
ADP/ATP translocator?  Nature 2004, 430:983-984.
11. Chevrollier A, Loiseau D, Chabi B, Renier G, Douay O, Malthiery Y,
Stepien G: ANT2 isoform required for cancer cell glycolysis.  J
Bioenerg Biomembr 2005, 37:307-316.
12. Zamora M, Merono C, Vinas O, Mampel T: Recruitment of NF-
kappaB into mitochondria is involved in adenine nucleotide
translocase (ANT1)-induced apoptosis.  J Biol Chem 2004,
279:38415-38423.
13. Hu MC, Hung MC: Role of IkappaB kinase in tumorigenesis.
Future Oncol 2005, 1:67-78.
14. Haefner B: Targeting NF-kappaB in anticancer adjunctive
chemotherapy.  Cancer Treat Res 2006, 130:219-245.
15. Karin M: NF-kappaB and cancer: Mechanisms and targets.  Mol
Carcinog 2006, 45:355-361.
16. Janek P, Briand P, Ian man I: The effect of estrone-progesterone
treatment on cell proliferation kinetics of hormone-depend-
ent GR mouse mammary tumors.  Cancer Res 1975,
35:3698-3704.
17. Green DR, Kroemer G: The pathophysiology of mitochondrial
cell death.  Science 2004, 305:626-629.
18. Galluzzi L, Larochette N, Zamzami N, Kroemer G: Mitochondria as
therapeutic targets for cancer chemotherapy.  Oncogene 2006,
25:4812-4830.
19. Green DR, Kroemer G: Pharmacological manipulation of cell
death: clinical applications in sight?  J Clin Invest 2005,
115:2610-2617.
20. Ferri KF, Kroemer G: Mitochondria-the  suicide organelles.
Bioessays 2001, 23:111-115.
21. Patterson S, Spahr CS, Daugas E, Susin SA, Irinopoulou T, Koehler C,
Kroemer G: Mass spectrometric identification of proteins
released from mitochondria undergoing permeability transi-
tion.  Cell Death Differ 2000, 7:137-144.
22. Halestrap AP, McStay GP, Clarke SJ: The permeability transition
pore complex: another view.  Biochimie 2002, 84:153-166.
23. Vyssokikh MY, Brdiczka D: The function of complexes between
the outer mitochondrial membrane pore (VDAC) and the
adenine nucleotide translocase in regulation of energy
metabolism and apoptosis.  Acta Biochim Pol 2003, 50:389-404.
24. Marzo I, Brenner C, Zamzami N, Jurgensmeier JM, Susin SA, Vieira
HL, Prevost MC, Xie Z, Matsuyama S, Reed JC, Kroemer G: Bax and
adenine nucleotide translocator cooperate in the mitochon-
drial control of apoptosis.  Science 1998, 281:2027-2031.
25. Belzacq AS, Vieira HL, Verrier F, Vandecasteele G, Cohen I, Prévost
MC, Larquet E, Pariselli F, Petit PX, Kahn A, Rizzuto R, Brenner C,
Kroemer G: Bcl-2 and Bax modulate adenine nucleotide
translocase activity.  Cancer Res 2003, 63:541-546.
26. Zamora M, Ortega JA, Alaña L, Viñas O, Mempel T: Apoptotic and
anti-proliferative effects of all-trans retionic acid. Adenine
nucleotide translocase sensitize HeLa cell to all-trans reti-
onic acid.  Exp Cell Res 2006, 312:1813-1819.
27. Le Bras M, Borgne-Sanchez A, Touat Z, El Dein OS, Deniaud A, Mail-
lier E, Lecellier G, Rebouillat D, Lemaire C, Kroemer G, Jacotot E,
Brenner C: Chemosensitization by knockdown of adenine
nucleotide translocase-2.  Cancer Res 2006, 66:9143-9152.
28. Du ZY, Qin RY, Xia W, Tian R, Kumar M: Gene transfer of soma-
tostatin receptor type 2 by intratumoral injection inhibits
established pancreatic carcinoma xenografts.  World J Gastro-
enterol 2005, 11:516-520.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/8/160/pre
pub